Table 1a.
Description of the cohort type, eligibility criteria, period of enrolment, and location of data collection of the adult or mixed (adult/paediatric) cohorts participating in COHERE (circa 2015)
| Cohort | Cohort Type | Eligibility criteria | Beginning of Enrollment | End of Enrollment | Data Collection | N Sites/ Countries | Location of sites |
|---|---|---|---|---|---|---|---|
| AHIVCOS | Hospital-based, Surveillance System | All HIV+ persons in care at 6/7 national centres | 1/1/1996 | Prospectively | 6 | Austria (National) | |
|
| |||||||
| AMACS | Clinic-based, Hospital-based | All HIV-1+ persons in at affiliated sites for at least 1 year, alive on 1/1/1996 | 1/1/1996 | Both prospectively and retrospectively | 13 | Greece (Regions : Attiki, Patras, Alexandroupolis) | |
|
| |||||||
| ANRS CO2 SEROCO | Interval cohort | HIV diagnosis <1 year before enrollment or a known date of infection identified by incomplete evokative Western-blot or an interval of less than 2 years between a negative and a positive ELISA | 1/1/1988 | 12/31/2009 | Prospectively | 25 | France (Paris area, Marseille, Nice) |
|
| |||||||
| ANRS CO3 AQUITAINE | Hospital-based | HIV-1+ >= age 13, seen at least once at a site & signed informed consent | 1/1/1987 | Prospectively | 13 | France (Region : Aquitaine) | |
|
| |||||||
| ANRS CO4 FHDH | Hospital-based | HIV-1 or HIV-2+ individuals who have provided written informed consent | 1/1/1989 | 12/31/2065 | Prospectively | 70 | France (National, except Aquitaine) |
|
| |||||||
| ANRS CO6 PRIMO | Interval cohort | HIV 1+ patients presenting during primary infection in sites | 1/1/1996 | Prospectively | 80 | France (National) | |
|
| |||||||
| ANRS CO8 APROCO-COPILOTE | Hospital-based | HIV-infected patients >= 18 years old, naive for protease inhibitors | 1/4/1997 | 6/6/1999 | Prospectively | 49 | France (National) |
|
| |||||||
| ANRS CO13 HEPAVIH | Hospital-based | Phase I : [12/2005, 12/2008]: HIV-1/HCV chronically infected >= age 18, Phase II : [9/2011, 3/2016]: HIV-1/HCV chronically infected >= age 18, beginning anti- HCV treatment comprising Telaprevir or Boceprevir, or having cleared HCV spontaneously in the absence of anti-HCV treatment. Phase III : [Q1/2014, Q1/2016] : Individuals who have received, are receiving, or will receive within the next 6 months combination therapy with new anti-HCV drugs, with or without peginterferon and/or ribavirin (temporary authorization, full marketing authorization, or within clinical trials) & individuals previously included in ANRS clinical trials evaluating new anti-HCV drugs |
11/10/2005 | Prospectively generally, and Prospective & Retrospective for Phase III | 27 | France (National) | |
|
| |||||||
| ATHENA | Clinic-based | Any HIV+ person entering care in one of the 27 adult (28 including Curacao) or 4 pediatric HIV treatment centers in the Netherlands and who does not object to standardized collection of data obtained as part of routine care | 1/1/1998 | Both prospectively and retrospectively | 31 | The Netherlands, Curacao (National) | |
|
| |||||||
| Bonn-Cologne Cohort | Clinic-based, Hospital-based | HIV+ | 1/5/1988 | Both prospectively and retrospectively | 2 | Germany (Bonn, Cologne) | |
|
| |||||||
| CASCADE | Clinic-based, Hospital-based | HIV+ with well estimated dates of HIV seroconversion | 1/1/1979 | Both prospectively and retrospectively | - | 11 countries* | |
|
| |||||||
| Clinserv | Clinic-based, Hospital-based | All patients HIV+ presenting at the clinical sites after 0/0/1999 | 1/1/1999 | Both prospectively and retrospectively | 18 | Germany | |
|
| |||||||
| CoRIS | Clinic-based | Confirmed HIV+, cART-naive, attending participating sitesl aged >16 & signed informed consent | 1/1/2004 | Prospectively | 37 | Spain (Multi-region) | |
| CoRIS-MD | Clinic-based | HIV+ | 1/1/1997 | 12/31/2003 | Retrospectively | 10 | Spain (Multi-region) |
|
| |||||||
| DHK | Hospital-based | HIV+ & in care in HIV treatment centres | 1/1/1995 | Prospectively | 8 | Denmark (National) | |
|
| |||||||
| ECS | Clinic-based, Hospital-based | Pregnant HIV+ women, diagnosed before or during pregnancy or as a result of HIV testing intrapartum, delivering liveborn infant. | 7/15/1985 | Prospectively | 10 countries | 10 countries^ | |
|
| |||||||
| EuroSIDA | Clinic-based, Hospital-based, Interval cohort | Aged > 16 & prebooked hospital appointment | 1/6/1994 | Both prospectively and retrospectively | 109 sites, 34 countries | 34 countries^^ | |
|
| |||||||
| Frankfurt | Clinic-based | HIV+ > age 16 in care at affiliated sites | 1/1/1987 | Prospectively | 5 | Germany (Frankfurt) | |
|
| |||||||
| Gemes Haemo | Clinic-based, Surveillance System | HIV+ haemophilics infected in early 1980s | 5/26/1999 | 4/26/1999 | Both prospectively and retrospectively | 2 | Spain (Madrid, Barcelona) |
|
| |||||||
| Georgian National HIV Cohort | Clinic-based, Hospital-based, Surveillance System | HIV+ adults | 1/1/2007 | Both prospectively and retrospectively | 1 | Georgia | |
|
| |||||||
| ICC (INMI Clinical Cohort) | Clinic-based, Hospital-based | HIV+ individuals in care at site | 1/1/1995 | Prospectively | 1 | Italy (Rome) | |
|
| |||||||
| ICONA | Hospital-based | HIV+, ART-naive, >= age 18 & signed informed consent | 1/1/1997 | Prospectively | 42 | Italy | |
|
| |||||||
| Infectious Disease Database (IDD) San Raffaele | Hospital-based | All HIV+ patients in care at site | 1/1/1991 | Prospectively | 1 | Italy (Milan) | |
|
| |||||||
| Italian MASTER Cohort | Clinic-based | HIV-1 or HIV-2+ (antibody test or positive HIV RNA) in care in participating sites | 1/1/1997 | Both prospectively and retrospectively | 8 | Italy (multi-city) | |
|
| |||||||
| Modena | Clinic-based | All new HIV diagnosis in adult patients (>= 18 year) since 1985, inhabitant in Province of Modena and reffered to Regional Surveillance System. Data were retrospectively collected from 1992. | 1/1/1992 | 12/31/2014 | Retrospectively | 1 | Italy (Modena) |
|
| |||||||
| PISCIS | Clinic-based, Hospital-based | HIV+ >= age 16 in care at one of the sites after January 1st 1998, irrespective of the stage of disease or degree of immunosuppression. | 1/1/1998 | Both prospectively and retrospectively | 11 | Spain (Region : Catalonia) | |
|
| |||||||
| SHCS | Clinic-based, Hospital-based | Any HIV+ persons >= age 18 | 1/1/1988 | Prospectively | 7 | Switzerland (National) | |
|
| |||||||
| St Pierre | Clinic-based, Hospital-based | HIV+ & at least one visit at affiliated sites | 1/25/1980 | Prospectively | 1 | Belgium (Brussels) | |
|
| |||||||
| Swedish InfCare HIV cohort | Clinic-based, Hospital-based, Surveillance System | All HIV+ persons in care in Sweden, opt out system | 1/1/1983 | Both prospectively and retrospectively | 29 | Sweden (National) | |
|
| |||||||
| UK Collaborative HIV Cohort Study (UK CHIC) | Clinic-based | HIV+ persons > age 16 & <= 1 visit at affilitated site after 1/1/1995 | 1/1/2001 | Both prospectively and retrospectively | 19 | United Kingdom (National) | |
|
| |||||||
| VACH | Hospital-based | HIV+ persons > age 16 & 1st visit at affiliated site. | 1/1/1997 | Prospectively | 23 | Spain | |
*
Austria, France, Germany, Greece, Italy, Netherlands, Norway, Spain (Badalona, Barcelona, Madrid Valencia), Sweden, Switzerland, United Kingdom
^
Belgium, Denmark, Germany, Netherlands, Poland, Italy, Spain, Sweden, Ukraine, United Kingdom
^^
Argentina, Austria, Belarus, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Georgia, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg,Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom)